(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 November 2012 (29.11.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/162068 A3

(51) International Patent Classification:
C07K 16/00 (2006.01) *C07K 1/00* (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2012/038227

(22) International Filing Date:
16 May 2012 (16.05.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/488,725 21 May 2011 (21.05.2011) US

(71) Applicant *(for all designated States except US)*: **MACROGENICS, INC.** [US/US]; 9640 Medical Center Drive, Rockville, MD 20850 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BONVINI, Ezio** [US/US]; 2 Shetland Ct., Rockville, MD 20851 (US). **BARAT, Bhaswati** [IN/US]; 15504 Villisca Terrace, Derwood, MD 20855 (US). **HUANG, Ling** [US/US]; 8210 Moorland Lane, Bethesda, MD 20817 (US). **JOHNSON, Leslie, S.** [US/US]; 14411 Poplar Hill Road, Darnestown, MD 20874 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

[Continued on next page]

(54) Title: DEIMMUNIZED SERUM-BINDING DOMAINS AND THEIR USE FOR EXTENDING SERUM HALF-LIFE

FIG.66



(57) Abstract: The disclosure is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunize serum-binding protein. Further disclosed are methods and uses that employ such molecules.

WO 2012/162068 A3

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
20 February 2014